Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1349 articles by Jacob Bell
-
BioMarin's hemophilia gene therapy recommended for approval in Europe
June 24, 2022 -
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
June 22, 2022 -
Galapagos, with latest deals, charts an unexpected journey to cell therapy
June 22, 2022 -
Roche Alzheimer's study fails in another setback to a long-tested hypothesis
June 16, 2022 -
With biotech in retreat, Third Rock raises $1B for life sciences investing
June 15, 2022 -
Amylyx's ALS drug gets approved in Canada
June 13, 2022 -
Vertex, CRISPR strengthen case for pioneering gene-editing treatment
June 11, 2022 -
Astellas, despite recent setbacks, opens $100M gene therapy plant
June 8, 2022 -
Amarin turns to job cuts as generics challenge its heart pill
June 6, 2022 -
Yumanity's days as an independent biotech come to a close
June 6, 2022 -
Detailed study data show modest benefit to Gilead breast cancer drug
June 4, 2022 -
Biohaven hits setback as it moves beyond migraine
May 23, 2022 -
AbbVie asks FDA to approve Parkinson's treatment
May 20, 2022 -
Gilead, having resolved manufacturing issues, forges ahead with HIV drug
May 17, 2022 -
Agios to cut jobs as it moves away from exploratory research
May 16, 2022 -
FDA approves oral version of Mitsubishi's ALS drug
May 13, 2022 -
Moderna's finance head is out as former employer conducts investigation
May 11, 2022 -
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
May 10, 2022 -
Against a historic market downturn, Moma Therapeutics raises $150M for precision cancer research
May 10, 2022 -
Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan
May 4, 2022 -
Biogen CEO to step down as company pulls back from Alzheimer's drug
May 3, 2022 -
A cancer biotech attracts another deep-pocketed partner in Gilead
May 2, 2022 -
AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis
April 29, 2022 -
After setbacks, a gene therapy company mulls a sale
April 28, 2022 -
Undeterred by gene therapy's struggles, a startup launches into a downturn
April 26, 2022